Clear All
12482 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
84679-0001-01 84679-0001 Melphalan Hydrochloride Melphalan Hydrochloride Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Nov 30, 2024 In Use
84651-0200-93 84651-0200 Taletrectinib IBTROZI 272.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Oral Jun 13, 2025 In Use
84577-0751-01 84577-0751 Gedatolisib REVTORPYK 180.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR, PI3K (⍺,β,ƍ,γ) Intravenous Jul 14, 2026 In Use
84549-0781-05 84549-0781 Triamcinolone Acetonide Triamcinolone Acetonide 40.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-arterial, Intramuscular Sep 8, 2025 In Use
84043-0200-30 84043-0200 Vepdegestrant VEPPANU 200.0 mg/1 Hormonal Therapy Proteolysis Targeting Chimera (PROTAC) ER, cereblon/CRBN Oral May 1, 2026 In Use
84043-0100-30 84043-0100 Vepdegestrant VEPPANU 100.0 mg/1 Hormonal Therapy Proteolysis Targeting Chimera (PROTAC) ER, Cereblon/CRBN Oral May 1, 2026 In Use
83980-0013-01 83980-0013 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 19, 2025 In Use
83980-0013-10 83980-0013 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 19, 2025 In Use
83980-0013-13 83980-0013 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 19, 2025 In Use
83980-0013-83 83980-0013 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 19, 2025 In Use
83980-0012-10 83980-0012 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 19, 2025 In Use
83980-0012-01 83980-0012 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 19, 2025 In Use
83980-0012-13 83980-0012 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 19, 2025 In Use
83980-0012-83 83980-0012 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 19, 2025 In Use
83858-0106-30 83858-0106 Dasatinib PHYRAGO 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
83858-0105-30 83858-0105 Dasatinib PHYRAGO 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
83858-0104-30 83858-0104 Dasatinib PHYRAGO 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
83858-0103-60 83858-0103 Dasatinib PHYRAGO 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
83858-0102-60 83858-0102 Dasatinib PHYRAGO 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
83858-0101-60 83858-0101 Dasatinib PHYRAGO 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
83831-0183-04 83831-0183 Bendamustine hydrochloride BENDAMUSTINE HYDROCHLORIDE 100.0 mg/4mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous May 29, 2026 In Use
83831-0164-10 83831-0164 Fluorouracil FAVLYXA 25.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Jul 15, 2026 In Use
83831-0159-02 83831-0159 Fulvestrant CLIGAVYX 250.0 mg/5mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Jul 1, 2026 In Use
83831-0153-01 83831-0153 Fosaprepitant NAVITRUX 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Jul 23, 2026 In Use
83831-0149-50 83831-0149 Leucovorin calcium VYKOURA 500.0 mg/50mL Ancillary Therapy Chemoprotective Antidote Intramuscular, Intravenous Mar 16, 2026 In Use

Found 12482 results — Export these results